Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Bristol, TN
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Bristol, TN
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Chattanooga, TN
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Johnson City, TN
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Johnson City, TN
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Kingsport, TN
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Kingsport, TN
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Memphis, TN
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Nashville, TN
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Arlington, TX
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Arlington, TX
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Austin, TX
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Carrollton, TX
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Carrollton, TX
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Dallas, TX
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Houston, TX
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Missouri City, TX
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Missouri City, TX
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
New Braunfels, TX
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
New Braunfels, TX
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
San Antonio, TX
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Sugar Land, TX
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Waco, TX
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Waco, TX
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Bountiful, UT
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Bountiful, UT
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Clinton, UT
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Clinton, UT
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Riverton, UT
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Riverton, UT
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Richmond, VA
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Virginia Beach, VA
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Winchester, VA
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Winchester, VA
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Renton, WA
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Renton, WA
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Spokane, WA
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Graz,
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Graz,
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Van Nuys, CA
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Van Nuys, CA
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Gainesville, FL
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Hopewell Junction, NY
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Hopewell Junction, NY
Click here to add this to my saved trials
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated:  12/31/1969
Limb Preservation Platform
mi
from
Fresno, CA
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated: 12/31/1969
Limb Preservation Platform
mi
from
Fresno, CA
Click here to add this to my saved trials
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated:  12/31/1969
The Miller Care Group
mi
from
Indianapolis, IN
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated: 12/31/1969
The Miller Care Group
mi
from
Indianapolis, IN
Click here to add this to my saved trials
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated:  12/31/1969
Wound Institute & Research Center
mi
from
Dunmore, PA
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated: 12/31/1969
Wound Institute & Research Center
mi
from
Dunmore, PA
Click here to add this to my saved trials
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated:  12/31/1969
Temple University School of Pediatric Medicine
mi
from
Philadelphia, PA
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated: 12/31/1969
Temple University School of Pediatric Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated:  12/31/1969
Richard C. Galperin, DPM, FAPWCA
mi
from
Dallas, TX
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated: 12/31/1969
Richard C. Galperin, DPM, FAPWCA
mi
from
Dallas, TX
Click here to add this to my saved trials
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated:  12/31/1969
The Wound Treatment Center
mi
from
Opelousas, LA
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated: 12/31/1969
The Wound Treatment Center
mi
from
Opelousas, LA
Click here to add this to my saved trials
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated:  12/31/1969
Futuro Clinical Trials, LLC
mi
from
McAllen, TX
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)
Status: Enrolling
Updated: 12/31/1969
Futuro Clinical Trials, LLC
mi
from
McAllen, TX
Click here to add this to my saved trials
Macronutrient Effects on Alzheimer's Disease (MEAL-2)
Macronutrient Effects on Alzheimer's Disease: HTN and IR (Hypertension and Insulin Resistance) (MEAL-2)
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Macronutrient Effects on Alzheimer's Disease (MEAL-2)
Macronutrient Effects on Alzheimer's Disease: HTN and IR (Hypertension and Insulin Resistance) (MEAL-2)
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
AMCR Institute, Inc
mi
from
Escondido, CA
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
AMCR Institute, Inc
mi
from
Escondido, CA
Click here to add this to my saved trials
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Stanford University Medical Center
mi
from
Palo Alto, CA
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Barbara Davis Center for Childhood Diabetes (Adult)
mi
from
Aurora, CO
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Barbara Davis Center for Childhood Diabetes (Adult)
mi
from
Aurora, CO
Click here to add this to my saved trials
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Barbara Davis Center for Childhood Diabetes (Pediatric)
mi
from
Aurora, CO
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Barbara Davis Center for Childhood Diabetes (Pediatric)
mi
from
Aurora, CO
Click here to add this to my saved trials
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Atlanta Diabetes Associates
mi
from
Atlanta, GA
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Atlanta Diabetes Associates
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Park Nicollet Clinic-International Diabetes Center - Adult and Pediatric
mi
from
Minneapolis, MN
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Park Nicollet Clinic-International Diabetes Center - Adult and Pediatric
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Rainer Clinical Research Center, Inc.
mi
from
Renton, WA
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Rainer Clinical Research Center, Inc.
mi
from
Renton, WA
Click here to add this to my saved trials
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Institute of Endocrinology, Sheba Medical Center
mi
from
Tel Aviv,
Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes
Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Institute of Endocrinology, Sheba Medical Center
mi
from
Tel Aviv,
Click here to add this to my saved trials
Negative Pressure Wound Therapy as a Drug Delivery System
Negative Pressure Wound Therapy as a Drug Delivery System
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center at Dallas
mi
from
Dallas, TX
Negative Pressure Wound Therapy as a Drug Delivery System
Negative Pressure Wound Therapy as a Drug Delivery System
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center at Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Impact of a Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With T2 Diabetes
The Impact of a Comprehensive Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Doctors Hospital At Renaissance
mi
from
Edinburg, TX
Impact of a Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With T2 Diabetes
The Impact of a Comprehensive Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Doctors Hospital At Renaissance
mi
from
Edinburg, TX
Click here to add this to my saved trials
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Birmingham, AL
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Mobile, AL
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials